Go homepage(回首页) Upload pictures (上传图片) Write articles (发文字帖)
The author:(作者)hpmailerpublished in(发表于) 2013/11/19 11:54:25 Tsinghua University research can detect one drop of blood test for lung cancer Kit
Draw a drop of blood in the lung cancer, after 2 hours, will be able to pass a kit for detecting changes, for doctors to provide assistance. Tsinghua University announced yesterday morning, the school of life research group headed by Professor Luo Yongzhang, discovery of heat shock protein 90 Alpha International (Hsp90 Alpha) tumor markers for a completely new, independent research and development of heat-shock 90 alpha and quantitative assay Kit has also been verified by clinical trials, won the State class III (highest level), medical devices certificates, and certification by the European Union.
According to reports, this blood test means more economic than traditional means of testing CT, convenient, but it is not yet complete pricing procedures.
Seed people
Tumor markers
Heat shock protein 90 Alpha content the higher the stronger the malignant tumor
Qinghua University professor Luo Yongzhang introduction, by revealing the presence of tumor markers or quantity, you can prompt the nature of the tumor, helping doctors to cancer treatment, solutions to current cancer patients found it later to a certain extent, higher mortality problems before the tumor metastasis.
Research group studying years, Luo Yongzhang, who found that the secretory heat shock protein Hsp90 Alpha promotes tumor invasion and metastasis, and its concentration in the blood is is positively associated with malignant tumors, malignant grade higher, higher levels of Hsp90 alpha, "the discovery provides a potential target for cancer treatment".
On this basis, Luo Yongzhang group collaboration with biotech companies, captured after a series of technical difficulties, successfully developed Hsp90 Alpha quantitative assay Kit.
At present, this quantitative assay Kit has been the national third class (the highest category) medical devices certificates, and certification by the European Union, can enter the domestic and European markets.
Luo Yongzhang describes, in accordance with the principle, you only need a single drop of blood, through quantitative assay Kit, and Hsp90 Alpha content is detected, the product can be used in various hospitals, the cost is not high, and was going to market this year, but pricing procedures have not been through, they are currently active and relevant departments to facilitate the completion of the relevant procedures.
Test Kit
Using more economical blood tests with high accuracy compared to a CT
Hsp90 Alpha quantitative assay Kit, whether early screening for cancer?
Yesterday, Luo Yongzhang Beijing news reporters that they want to come to this conclusion, but by checking for any single tumor markers were able to determine whether the patient is suffering from cancer, should view the tumor slices to make this determination. However, he said, has 8 domestic Chinese Academy of medical sciences Cancer Hospital within the hospital completed a lung cancer clinical trial, proved by detection of Hsp90 Alpha content, can help doctors monitor the patient's condition and evaluation of diagnosis and treatment.
Shi yuankai, Vice President of Chinese Academy of medical sciences Cancer Hospital confirmed that the hospital clinical tests carried out showed that average Hsp90 Alpha content in the serum of patients with lung cancer and pulmonary benign lesions and to be much higher than the average person, and accordingly, Hsp90 Alpha contents in patients with advanced lung cancer, are higher than in patients with early stage lung cancer. "When Hsp90 Alpha in patients with an average of more than 34%, explains cancer development. ”
Shi yuankai said, according to the results, and Hsp90 Alpha diagnostic accuracy than traditional lung cancer tumor markers of carcinoembryonic Antigen and Cytokeratin, the "use of such blood tests than patients repeatedly to do CT to more economical and convenient. ”
Currently, Hsp90 alpha testing other tumors, such as liver cancer, stomach cancer, breast cancer, prostate cancer, pancreatic cancer and colorectal cancer clinical trials are expected to be completed within one year.
Glossary
Luo Yongzhang introduction, tumor marker is a type of reflecting tumor substances content in the patients with tumor than healthy people, is a cancer diagnosis, prognosis and treatment guidelines important adjunct. In 2011, the United States National Cancer Institute announced a 31 was clear for cancer detection products around the globe, with blood for the detection of 17 objects, are defined by the foreign scientists and, to date there is no autonomous discovery of tumor markers in clinical practice is widely used and recognized.
Heat shock proteins
According to reports, the HSP (Heat shock proteins, abbreviated HSPs) cells in certain environmental factors or stress stimulation of formation of species with characteristics of molecular chaperone proteins, widespread in various cells from bacteria to mammals. Heat shock protein 90 in human α (Hsp90 Alpha) is an important member of the family of heat shock proteins. 1989 foreign experts Hsp90 Alpha genes sequences were first reported, confirming the identity of the protein. In 1992, foreign scientists have found that Hsp90 Alpha tumor cells can be secreted into the extracellular, but its secretion of the regulatory mechanisms in place for a long time remained unclear.
The Beijing News reporter Xu Luyang
(Original title: disease blood test for lung cancer)
只要在肺癌患者身上抽取一滴血，2小时后，就能通过一个试剂盒检测出病情变化，为医生诊断提供辅助。清华大学昨日上午宣布，该校生命学院教授罗永章率领的课题组，在国际上首次发现热休克蛋白90α(Hsp90α)为一个全新的肿瘤标志物，自主研发的热休克90α定量检测试剂盒也已通过临床试验验证，获得国家第三类(最高级别)医疗器械证书，并通过欧盟认证。
据介绍，这种血液检测手段将比传统检测CT手段更为经济、方便，但目前尚未完成定价手续。
专家简介
肿瘤标志物
热休克蛋白90α 含量越高 肿瘤恶性越强
清华大学教授罗永章介绍，通过揭示肿瘤标志物的存在或量变，可以提示肿瘤的性质，帮助医生对肿瘤进行诊疗，一定程度上解决目前肿瘤患者发现病情晚，在肿瘤转移前死亡率较高的问题。
经课题组多年研究，罗永章等人发现，分泌型热休克蛋白Hsp90α能促进肿瘤侵袭及转移，且其在血液中的含量与肿瘤恶性都呈正相关，即肿瘤恶性程度越高，Hsp90α的含量也越高，“该发现为癌症治疗提供了一个潜在靶点”。
在此基础上，罗永章课题组与生物科技公司合作，攻克一系列技术难题后，成功研发出Hsp90α定量检测试剂盒。
目前，这个定量检测试剂盒已获得国家第三类(最高类别)医疗器械证书，并通过欧盟认证，可进入国内和欧盟市场。
罗永章介绍，按照原理，只需要一滴血，通过定量检测试剂盒，就能检测出Hsp90α含量，该产品可以在各个医院使用，成本也不高，原本准备今年上市，但定价手续尚未走完，目前他们正在积极和有关部门推动完成相关手续。
检测试剂盒
利用血液检测 准确率高 比做CT更经济
利用Hsp90α定量检测试剂盒，能否对癌症进行早期筛查？
昨日，罗永章对新京报记者表示，自己希望得到这个结论，但目前通过检查任何单一的肿瘤标志物，都不能确定患者是否患有肿瘤，需查看肿瘤切片才能确定。但他表示，目前已在中国医学科学院肿瘤医院等国内8家三甲医院内，完成了肺癌临床试验，证明通过检测Hsp90α含量，可帮助医生监测患者病情和进行诊疗评价。
中国医学科学院肿瘤医院副院长石远凯证实，该院进行的临床试验显示，肺癌患者血中Hsp90α含量平均值，要远高于肺部良性病变及普通人；相应地，肺癌中晚期患者体内Hsp90α含量，要高于肺癌早期患者。“当患者Hsp90α平均值变化超过34%时，说明肿瘤发展了。”
石远凯说，根据结果显示，Hsp90α的诊断准确率，要高于传统肺癌肿瘤标志物癌胚抗原及细胞角蛋白，“利用这种血液检测还比让患者多次去做CT要更经济、方便。”
目前，利用Hsp90α检测其他肿瘤，如肝癌、胃癌、乳腺癌、前列腺癌、胰腺癌、结直肠癌的临床试验也有望在一年内完成。
名词解释
罗永章介绍，肿瘤标志物是一类反映肿瘤存在的物质，在肿瘤患者中的含量远远超过健康人，是肿瘤诊断、预后及治疗指导的重要辅助手段。2011年，美国国家癌症研究院公布了全球31个被明确用于癌症检测的产品，其中以血液为检测对象的有17个，均由外国科学家发现和定义，至今尚无我国自主发现的肿瘤标志物在临床中被广泛应用和认可。
热休克蛋白
据介绍，热休克蛋白(Heat shock proteins，英文简称HSPs)是细胞在某些环境因素或应激条件刺激下形成的一类具有分子伴侣特性的蛋白质，广泛存在于从细菌到哺乳动物的各类细胞中。人热休克蛋白90α(Hsp90α)是热休克蛋白家族中的重要成员。1989年国外专家首次报道了Hsp90α的基因序列，确认了该蛋白的身份。1992年外国科学家发现，Hsp90α能被肿瘤细胞分泌到细胞外，但其分泌调控机制在此后很长时间仍不清楚。
新京报记者 许路阳
(原标题：肺癌病情滴血可测)
赞